The invention provides antitumour compounds of formula (I), wherein R
1
is an aromatic substituent; R
2
is hydrogen or a substituent when the dotted line is absent, or R
2
is absent when the dotted line represents a bond to give a double bond between the nitrogen which bears R
2
and the carbon which bears R
3
; R
3
is an oxo group ═O when the dotted line is absent or is a substituent when the dotted line represents a bond to give a double bond between the nitrogen bearing R
2
and the carbon bearing R
3
; R
4
is hydrogen or a substituent; and pharmaceutically acceptable salts thereof.
[EN] DERIVATIVES OF VARIOLIN B<br/>[FR] DÉRIVÉS DE VARIOLINE B
申请人:UNIV BARCELONA
公开号:WO2002012240A1
公开(公告)日:2002-02-14
The invention provides antitumour compounds of formula (I), wherein R1 is an aromatic substituent; R2 is hydrogen or a substituent when the dotted line is absent, or R2 is absent when the dotted line represents a bond to give a double bond between the nitrogen which bears R2 and the carbon which bears R3; R3 is an oxo group = O when the dotted line is absent or is a substituent when the dotted line represents a bond to give a double bond between the nitrogen bearing R2 and the carbon bearing R3; R4 is hydrogen or a substituent; and pharmaceutically acceptable salts thereof.
The invention provides antitumour compounds of formula (I), wherein R
1
is an aromatic substituent; R
2
is hydrogen or a substituent when the dotted line is absent, or R
2
is absent when the dotted line represents a bond to give a double bond between the nitrogen which bears R
2
and the carbon which bears R
3
; R
3
is an oxo group =0 when the dotted line is absent or is a substituent when the dotted line represents a bond to give a double bond between the nitrogen bearing R
2
and the carbon bearing R
3
; R
4
is hydrogen or a substituent; and pharmaceutically acceptable salts thereof.
The invention provides antitumour compounds of formula (I), wherein R1 is an aromatic substituent; R2 is hydrogen or a substituent when the dotted line is absent, or R2 is absent when the dotted line represents a bond to give a double bond between the nitrogen which bears R2 and the carbon which bears R3; R3 is an oxo group ═O when the dotted line is absent or is a substituent when the dotted line represents a bond to give a double bond between the nitrogen bearing R2 and the carbon bearing R3; R4 is hydrogen or a substituent; and pharmaceutically acceptable salts thereof.